Britain and America have signed a landmark trade agreement that will keep zero tariffs on UK pharmaceutical shipments going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to boost funding on drugs through the NHS. This commitment ensures that import taxes on these vital products will be held at nothing for a timeframe of the next three years.
This agreement follows previous statements to significantly raise import taxes on patented drug imports, with increases mentioned as high as one hundred percent.
"This deal with the United Kingdom bolsters the global environment for cutting-edge drugs and introduces long-overdue balance to American-British medicine commerce," an announcement declared.
Trade Importance
Drugs are one of the the United Kingdom's largest exports to the United States, which is easily the biggest buyer for large companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period to the end of the third quarter, the UK exported pharmaceutical products valued at £11.1bn to the US. This figure made up a significant portion of total UK exports in that span.
"This guarantee protects jobs, increases funding and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary remarked.
Detailed NHS Changes
The agreement involves several key changes from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase total NHS spending on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must pay back to the NHS to control costs will be restricted at 15%. Previously, rebates were more than 20%.
Broader Context
This agreement comes amid a protracted tension between the sector and the ministers over medicine costs and approval rates.
These tensions were exacerbated by arguments that US customers were charged significantly more for the same drugs than people in the Britain and the EU.
Recently, several major drug company projects in the UK have been delayed or scrapped, while substantial expansions have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had declined as a percentage of its total funding over the last ten years.
